Jeff Bird focuses on healthcare, including biotechnology and medical devices. Recent Series A investments include Forty Seven Inc. (monoclonal antibody immuno-oncology therapies) and XIOS Therapeutics (small molecular immuno-oncology.) In the genomics space, Jeff is a co-investor with Illumina in Helix (consumer genomics marketplace) and GRAIL (cancer screening test). Jeff was CEO and an investor at Verinata Health (noninvasive prenatal diagnosis). After their acquisition by Illumina in early 2013, he served as their GM for a year. He is currently a board member at NuGen Technologies(research reagents), Portola Pharmaceuticals (PTLA,a spin-out of Cor/Millennium focused on cardiovascular therapeutics), Restoration Robotics (aesthetic surgery devices), and Teneobio (next generation antibodies). He also represents the firm’s investments in Acceleron Pharmaceuticals (XLRN, metabolic therapeutics) and Pacific Biosciences (PACB, DNA sequencing). Jeff was formerly a director at Horizon Pharma (HZNP), Akarx Inc., (acquired by MGI Pharma in 2008), BARRX Medical, Inc. (acquired by Covidien in 2012) and Idun Pharmaceuticals, (acquired by Pfizer in 2005). Jeff was previously Senior Vice President, Business Operations at Gilead Sciences, where he worked from 1988 to 1990 and then 1992 to 2000. He was primarily responsible for several alliances with major pharmaceutical companies and helped Gilead to acquire NeXstar in a $550 million transaction. His commercial responsibilities included direct sales in the US and Europe. Jeff received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School.